KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis.

Guillemette de la Borderie, Damien Chimits, Babak Boroojerdi, Melissa Brock, Petra W Duda, Fiona Grimson, Paul Mahoney, Foteini Strimenopoulou, Gary Cutter, Inmaculada Aban, Susanna Brauner, Malin Petersson, James F Howard, Nathan Bennett

Ther Adv Neurol Disord 17 17562864241279125

PMID39314260
PMCIDPMC11418339
DOI10.1177/17562864241279125
发表日期2024-09-24
摘要

摘要

BACKGROUND: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucoplan data past 12 weeks are not available. OBJECTIVES: Predict the treatment effect of zilucoplan versus control (placebo or standard of care) in patients with gMG up to 24 weeks. DESIGN: A model-informed analysis (MIA) within a Bayesian framework. METHODS: Part 1 of the MIA comprised a control meta-regression using aggregate data on control response over time from randomised studies and a national myasthenia gravis (MG) registry. In Part 2, a combined Bayesian analysis of individual patient-level data from the phase II (NCT03315130), RAISE (NCT04115293) and RAISE-XT (NCT04225871) studies of zilucoplan was conducted using posterior distributions from Part 1 as informative priors. Population mean treatment effect in the change from baseline (CFB) at week 24 in MG-Activities of Daily Living (MG-ADL) and quantitative MG (QMG) scores for zilucoplan versus control were assessed. RESULTS: At week 24, the predicted mean CFB in MG-ADL score was -4.55 (95% credible interval: -6.04, -3.13) with zilucoplan versus -2.00 (-3.35, -0.64) with control (difference: -2.55 [-3.76, -1.40]). The probability of a favourable treatment effect as measured by MG-ADL score at week 24 with zilucoplan versus control was >99.9%. There was an 82.8% probability that the difference in the predicted mean CFB in MG-ADL score at week 24 was greater than the clinically meaningful threshold (⩾2.0-point improvement). Comparable results were observed with QMG. CONCLUSION: This MIA demonstrates the maintenance of efficacy with zilucoplan versus control up to 24 weeks. Through combining real-world evidence with data from randomised studies, this novel method to estimate long-term treatment efficacy facilitated reduced exposure to placebo in the phase III RAISE study. This methodology could be used to reduce the length of future placebo-controlled studies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。